Transient and persistent antibodies against TNF-inhibitors in IBD

American Journal of Gastroenterology

Volumn 110, Issue 11, 2015, Pages 1623-1624

  Steenholdt, Casper ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; ANTIBODY; MONOCLONAL ANTIBODY;

DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; INFLAMMATORY BOWEL DISEASE; LETTER; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; FEMALE; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MALE;

ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE;

EID: 84948798916     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.325     Document Type: Letter

References (9)

1. Paul S, Dronne W, Roblin X. Kinetics of antibodies against adalimumab are not associated with poor outcomes in IBD. Am J Gastroenterol 2015; 110: 777-8
2. Steenholdt C, Al-Khalaf M, Brynskov J et al. Clinical implications of variations in antiinfl iximab antibody levels in patients with infl ammatory bowel disease. Infl amm Bowel Dis 2012; 18: 2209-17
3. Vande Casteele N, Gils A, Singh S et al. Antibody response to infl iximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013; 108: 962-71
4. Ungar B, Chowers Y, Yavzori M et al. The temporal evolution of antidrug antibodies in patients with infl ammatory bowel disease treated with infl iximab. Gut 2014; 63: 1258-64
5. Steenholdt C, Frederiksen MT, Bendtzen K et al. Time course and clinical implications of development of antibodies against adalimumab in patients with infl ammatory bowel disease. J Clin Gastroenterol, advance online publication, 9 July 2015 [e-pub ahead of print].
6. Steenholdt C, Bendtzen K, Brynskov J et al. Changes in serum trough levels of infl iximab during treatment intensifi cation but not in anti-infl iximab antibody detection are associated with clinical outcomes aft er therapeutic failure in crohn's disease. J Crohns Colitis 2015; 9: 238-45
7. Ben-Horin S, Waterman M, Kopylov U et al. Addition of an immunomodulator to infl iximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with infl ammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 444-7
8. Steenholdt C, Bendtzen K, Brynskov J et al. Clinical implications of measuring drug and anti-drug antibodies by diff erent assays when optimizing infl iximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol 2014; 109: 1055-64
9. Steenholdt C, Brynskov J, Th omsen OO et al. Individualised therapy is more cost-eff ective than dose intensifi cation in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014; 63: 919-27